Clinical Evaluation of Plasma Decoy Receptor 3 Levels in Silicosis

[1]  T. Otsuki,et al.  Autoantibodies in Silicosis Patients: Silica-Induced Dysregulation of Autoimmunity , 2017, Autoantibodies and Cytokines.

[2]  W. Fujimoto,et al.  Clinical evaluation of CENP-B and Scl-70 autoantibodies in silicosis patients , 2017, Experimental and therapeutic medicine.

[3]  T. Otsuki,et al.  Silicosis and autoimmunity , 2017, Current opinion in allergy and clinical immunology.

[4]  S. Hsieh,et al.  Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients. , 2017, Journal of the Formosan Medical Association = Taiwan yi zhi.

[5]  H. Matsuzaki,et al.  Environmental factors and human health: fibrous and particulate substance-induced immunological disorders and construction of a health-promoting living environment , 2016, Environmental Health and Preventive Medicine.

[6]  P. Moog,et al.  Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives , 2015, Therapeutics and clinical risk management.

[7]  M. Kurosaka,et al.  Decoy receptor 3 regulates the expression of tryptophan hydroxylase 1 in rheumatoid synovial fibroblasts. , 2015, Molecular medicine reports.

[8]  P. Sfikakis,et al.  The TL1A/DR3/DcR3 pathway in autoimmune rheumatic diseases. , 2015, Seminars in arthritis and rheumatism.

[9]  Yanqiang Hou,et al.  Decoy Receptor 3 Improves Survival in Experimental Sepsis by Suppressing the Inflammatory Response and Lymphocyte Apoptosis , 2015, PloS one.

[10]  L. Xia,et al.  Serum and synovial fluid levels of tumor necrosis factor-like ligand 1A and decoy receptor 3 in rheumatoid arthritis. , 2015, Cytokine.

[11]  A. Kistler,et al.  The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). , 2015, Swiss medical weekly.

[12]  Weidong Jin,et al.  The expression of death decoy receptor 3 was increased in the patients with primary Sjögren’s syndrome , 2015, Clinical Rheumatology.

[13]  R. B. Jones,et al.  Rituximab in the Treatment of Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis , 2014, Nephron Clinical Practice.

[14]  Ying Chen,et al.  Silica exposure and altered regulation of autoimmunity , 2014, Environmental Health and Preventive Medicine.

[15]  Ming-Huang Chen,et al.  Decoy receptor 3 suppresses B cell functions and has a negative correlation with disease activity in rheumatoid arthritis. , 2014, Clinical and Experimental Rheumatology.

[16]  L. Guillevin.  Rituximab for ANCA-associated vasculitides. , 2014, Clinical and experimental rheumatology.

[17]  K. Costenbader,et al.  The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. , 2013, Autoimmunity reviews.

[18]  E. Wouters,et al.  Silica induces NLRP3 inflammasome activation in human lung epithelial cells , 2013, Particle and Fibre Toxicology.

[19]  W. Fujimoto,et al.  Immunological Effects of Silica and Related Dysregulation of Autoimmunity , 2011 .

[20]  C. Coban,et al.  Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. , 2011, Immunity.

[21]  T. Otsuki,et al.  Dysregulation of autoimmunity caused by silica exposure: Fas-mediated apoptosis in T lymphocytes derived from silicosis patients , 2011 .

[22]  S. Murakami,et al.  Reductive Alteration of the Regulatory Function of the CD4+CD25+ T Cell Fraction in Silicosis Patients , 2010, International journal of immunopathology and pharmacology.

[23]  Y. Hamaguchi.  Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis , 2010, The Journal of dermatology.

[24]  S. Murakami,et al.  Soluble Interleukin-2 Receptor as an Indicator of Immunological Disturbance Found in Silicosis Patients , 2009, International journal of immunopathology and pharmacology.

[25]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[26]  K. Cutroneo.  TGF‐β–induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring , 2007, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[27]  A. Ueki,et al.  Alterations of Fas and Fas-Related Molecules in Patients with Silicosis , 2006, Experimental biology and medicine.

[28]  W. Fujimoto,et al.  Detection, epitope‐mapping and function of anti‐Fas autoantibody in patients with silicosis , 2005, Immunology.

[29]  Y. Isozaki,et al.  Anti‐Caspase‐8 Autoantibody Response in Silicosis Patients is Associated with HLA‐DRB1, DQB1 and DPB1 Alleles , 2005, Journal of occupational health.

[30]  T. Saeki,et al.  Two cases of hypertrophic pachymeningitis associated with myeloperoxidase antineutrophil cytoplasmic autoantibody (MPO-ANCA)-positive pulmonary silicosis in tunnel workers , 2004, Clinical Rheumatology.

[31]  J. Hamilton.  Nondisposable materials, chronic inflammation, and adjuvant action , 2003, Journal of leukocyte biology.

[32]  Y. Isozaki,et al.  Intramolecular epitope spreading among anti‐caspase‐8 autoantibodies in patients with silicosis, systemic sclerosis and systemic lupus erythematosus, as well as in healthy individuals , 2002, Clinical and experimental immunology.

[33]  G. Cooper,et al.  Occupational exposures and autoimmune diseases. , 2002, International immunopharmacology.

[34]  M. Alavi,et al.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis , 2002, Annals of the rheumatic diseases.

[35]  H. Ihn.  The role of TGF-beta signaling in the pathogenesis of fibrosis in scleroderma. , 2002, Archivum immunologiae et therapiae experimentalis.

[36]  H. Sakaguchi,et al.  Autoantibodies detectable in the sera of silicosis patients. The relationship between the anti-topoisomerase I antibody response and HLA-DQB1*0402 allele in Japanese silicosis patients. , 2001, The Science of the total environment.

[37]  A. Ueki,et al.  Antidesmoglein Autoantibodies in Silicosis Patients with No Bullous Diseases , 2001, Dermatology.

[38]  V. Castranova,et al.  Silicosis and coal workers' pneumoconiosis. , 2000, Environmental health perspectives.

[39]  Otsuki,et al.  Over‐expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients , 2000, Clinical and experimental immunology.

[40]  Jeffrey B. Kopp,et al.  TGF- and fibrosis , 1999 .

[41]  Kishimoto,et al.  Serum levels of soluble Fas ligand in patients with silicosis , 1999, Clinical and experimental immunology.

[42]  N. McHugh,et al.  Serologic abnormalities in systemic sclerosis. , 1999, Current opinion in rheumatology.

[43]  G. Cooper,et al.  Occupational exposure to crystalline silica and autoimmune disease. , 1999, Environmental health perspectives.

[44]  V. Dixit,et al.  Apoptosis control by death and decoy receptors. , 1999, Current opinion in cell biology.

[45]  D. Botstein,et al.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer , 1998, Nature.

[46]  H. Sakaguchi,et al.  Soluble Fas mRNA is dominantly expressed in cases with silicosis , 1998, Immunology.

[47]  A. Churg,et al.  Mechanisms in the pathogenesis of asbestosis and silicosis. , 1998, American journal of respiratory and critical care medicine.

[48]  Y. Isozaki,et al.  Elevated soluble Fas/APO‐1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours , 1997, Clinical and experimental immunology.

[49]  G. Wagner.  Asbestosis and silicosis , 1997, The Lancet.

[50]  P. D’Haese,et al.  ANCA-associated diseases and silica exposure , 1997, Clinical reviews in allergy & immunology.

[51]  K. Steenland,et al.  Silica exposure and autoimmune diseases. , 1995, American journal of industrial medicine.

[52]  L. Privalova,et al.  On the relationship between activation and breakdown of macrophages in the pathogenesis of silicosis (an overview). , 1995, La Medicina del lavoro.

[53]  N. Lapp,et al.  How silicosis and coal workers' pneumoconiosis develop--a cellular assessment. , 1993, Occupational medicine.

[54]  S. Jabłońska,et al.  Immunological markers of the subsets of systemic scleroderma and its overlap. , 1991, Archivum Immunologiae et Therapiae Experimentalis.

[55]  R. A. McReynolds,et al.  Immunotoxicology of silica. , 1982, Critical reviews in toxicology.

[56]  A. G. Heppleston.  SILICA AND ASBESTOS: CONTRASTS IN TISSUE RESPONSE , 1979, Annals of the New York Academy of Sciences.

[57]  A. Caplan.  Certain Unusual Radiological Appearances in the Chest of Coal-miners Suffering from Rheumatoid Arthritis , 1953, Thorax.